

Section 2: 510(k) Summary (21 CFR § 807.92)

Submitter: Avinger, Inc.
400 Chesapeake Drive
Redwood City, CA 94063

Contact: Himanshu Patel
Chief Technology Officer

Date Summary Prepared: 12 July 2010

Device Trade Name: Wildcat 5F Guidewire Support Catheter

Common Name: Guidewire Support Catheter

Classification Name: Percutaneous Catheter (21 CFR § 870.1250)

Product Code: DQY

Cleared Device: Wildcat 7F Guidewire Support Catheter (K083313)

AUG 06 2010

Device Description:

The Wildcat 5F Guidewire Support Catheter is a 5F sheath and 0.014" guidewire compatible over-the-wire device. It consists of a catheter shaft with handle assembly at the proximal end and an atraumatic distal tip. The catheter has a working length of 140 cm. A locking luer connector at the proximal end provides entry to a lumen that supports and facilitates movement of a guidewire. The catheter has been irradiated for sterility and is intended for single use only.

Intended Use:

The Wildcat 5F Guidewire Support Catheter is intended to be used to support steerable guidewires in accessing discrete regions of the peripheral vasculature. It may be used to facilitate placement and exchange of guidewires and other interventional devices. It may also be used to deliver saline/contrast.

Nonclinical Performance Data:

Design verification testing was conducted. Such testing confirms that the Wildcat 5F device performs according to the stated intended use. Device evaluation consisted of laboratory testing specified in 10555-1 "Sterile, single-use intravascular catheters – Part 1 – General Requirements" and included tensile, torque strength, coating integrity and device compatibility. Biocompatibility testing was conducted according to EN ISO 10993-1 "Biological Evaluation of Medical Devices". All data fell well within pre-determined product specifications and external standard requirements. In addition, device

performance was successfully evaluated in a porcine animal model. The test model represented a discrete vascular bed in the coronary arteries under GLP-like conditions.

Comparison with Cleared Device:

The Avinger 5F catheter is very similar to the Avinger 7F catheter. Both devices are intended for use with steerable guidewires to access discrete regions of the peripheral vasculature. Additionally, both devices may be used to facilitate placement and exchange of conventional guidewires and to deliver saline or contrast. Both devices are comprised of similar materials and function according to similar operating parameters. There are two primary differences between the modified and cleared devices. First, the modified device is smaller (5F as opposed to 7F) as compared to the cleared device. Secondly, the distal tip of the modified device is comprised of a single part with atraumatic exposed wedges as opposed to the retractable wedges contained in the larger device.

Summary:

Based upon the product technical information, intended use, performance and biocompatibility data provided in this premarket notification, the Avinger 5F catheter has been shown to be equivalent to the currently marketed Avinger 7F catheter.



Food and Drug Administration
10903 New Hampshire Avenue
Document Control Room -WO66-G609
Silver Spring, MD 20993-0002

AUG 06 2010

Avinger, Inc
c/o Mr. Himanshu Patel
Chief Technology Officer
400 Chesapeake Drive
Redwood City, CA 94063

Re: K101647

Trade/Device Name: Wildcat 5F Guidewire Support Catheter

Regulation Number: 21 CFR§ 870.1250

Regulation Name: Percutaneous Catheter

Regulatory Class: Class II

Product Code: DQY

Dated: July 14, 2010

Received: July 15, 2010

Dear Mr Patel:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.


Page 2 – Mr. Himanshu Patel

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to <http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm> for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm> for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address <http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm>.

Sincerely yours,



 Bram D. Zuckerman, M.D.
Director
Division of Cardiovascular
Office of Device Evaluation
Center for Devices and
Radiological Health

Enclosure

K101647

Section 1: Statement of Indications for Use

510(k) Number if known: ~~TBD~~ → K101647

Device Name: Wildcat 5F Guidewire Support Catheter

AUG 06 2010

Indications for Use:

The Wildcat 5F Guidewire Support Catheter is intended to be used to support steerable guidewires in accessing discrete regions of the peripheral vasculature. It may be used to facilitate placement and exchange of guidewires and other interventional devices. It may also be used to deliver saline/contrast.

Prescription Use:
(Per 21 CFR § 801, Subpart D)

AND/OR

Over-the-Counter Use _____
(Per 21 CFR §807, Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE – CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

[Signature]
(Division Sign-Off)

CONFIDENTIAL

Division of Cardiovascular Devices Page 2

510(k) Number K101647